MoonLake Immunotherapeutics (MLTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.06B
Last updated: Nov 17, 2026 at 11:06 AM ET
MoonLake Immunotherapeutics (MLTX) Earnings: Report Dates and Results
MoonLake Immunotherapeutics (MLTX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, MoonLake Immunotherapeutics reported EPS of -$0.93, below the -$0.77 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MLTX has an expected report date of Feb 22, 2027.
Earnings History
Of the 19 quarters below that had an estimate, MLTX beat 9, missed 9 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2022, when EPS landed 53.57% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.93 | -$0.77 | -$0.88 - -$0.66 | -20.78% | Miss | N/A | 7 | 6 up, 0 down | Nov 4, 2026 |
| Jun 30, 2026 | -$0.84 | -$0.90 | -$1.02 - -$0.75 | +6.67% | Beat | N/A | 8 | 2 up, 1 down | Aug 10, 2026 |
| Mar 31, 2026 | -$0.98 | -$0.92 | -$1.01 - -$0.81 | -6.52% | Miss | N/A | 8 | 2 up, 0 down | May 11, 2026 |
| Dec 31, 2025 | -$0.92 | -$0.98 | -$1.03 - -$0.88 | +6.05% | Beat | N/A | 8 | 1 up, 0 down | Feb 25, 2026 |
| Sep 30, 2025 | -$1.10 | -$0.89 | -$0.99 - -$0.84 | -23.60% | Miss | N/A | 7 | 0 up, 3 down | Nov 5, 2025 |
| Jun 30, 2025 | -$0.87 | -$0.76 | -$0.83 - -$0.70 | -14.47% | Miss | N/A | 7 | 4 up, 0 down | Aug 5, 2025 |
| Mar 31, 2025 | -$0.63 | -$0.74 | -$0.85 - -$0.54 | +14.34% | Beat | N/A | 9 | 0 up, 2 down | May 12, 2025 |
| Dec 31, 2024 | -$0.72 | -$0.59 | -$0.76 - -$0.39 | -22.03% | Miss | N/A | 9 | 0 up, 1 down | Feb 26, 2025 |
| Sep 30, 2024 | -$0.56 | -$0.45 | -$0.53 - -$0.33 | -24.44% | Miss | N/A | 15 | 0 up, 1 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.39 | -$0.28 | -$0.38 - -$0.22 | -39.29% | Miss | N/A | 13 | 0 up, 0 down | Aug 7, 2024 |
| Mar 31, 2024 | -$0.22 | -$0.21 | -$0.30 - -$0.11 | -4.76% | Miss | N/A | 11 | 0 up, 0 down | May 7, 2024 |
| Dec 31, 2023 | -$0.12 | -$0.23 | -$0.37 - -$0.15 | +47.83% | Beat | N/A | 13 | 1 up, 0 down | Feb 29, 2024 |
| Sep 30, 2023 | -$0.18 | -$0.25 | -$0.30 - -$0.13 | +28.00% | Beat | N/A | 12 | 0 up, 0 down | Nov 14, 2023 |
| Jun 30, 2023 | -$0.23 | -$0.29 | -$0.37 - -$0.21 | +20.69% | Beat | N/A | 10 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.23 | -$0.31 | -$0.44 - -$0.19 | +25.81% | Beat | N/A | 8 | 3 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.43 | -$0.28 | -$0.38 - -$0.28 | -53.57% | Miss | N/A | 7 | 0 up, 0 down | Mar 20, 2023 |
| Sep 30, 2022 | -$0.27 | -$0.34 | -$0.37 - -$0.29 | +20.59% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2022 |
| Jun 30, 2022 | -$0.34 | -$0.54 | N/A | +37.04% | Beat | N/A | 2 | 1 up, 1 down | Aug 12, 2022 |
| Mar 31, 2022 | -$0.35 | -$0.35 | N/A | 0.00% | In line | N/A | N/A | N/A | May 16, 2022 |
| Dec 31, 2021 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 17, 2022 |
| Sep 30, 2021 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 |
| Jun 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2021 |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 21, 2021 |
| Dec 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 |
| Sep 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Dec 3, 2020 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.52, after -$1.89 the year before. It was -$0.01 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.52 | N/A |
| Dec 31, 2024 | -$1.89 | N/A |
| Dec 31, 2023 | -$0.76 | N/A |
| Dec 31, 2022 | -$1.39 | N/A |
| Dec 31, 2021 | -$0.31 | N/A |
| Dec 31, 2020 | -$0.01 | N/A |
Frequently Asked Questions About MLTX
When is MoonLake Immunotherapeutics's next earnings date?
MoonLake Immunotherapeutics's next earnings report is expected for Feb 22, 2027.
Did MLTX beat earnings estimates last quarter?
No. MoonLake Immunotherapeutics reported EPS of -$0.93 for the quarter ended Sep 30, 2026, below the -$0.77 estimate by 20.78%.
What EPS do analysts expect from MLTX next quarter?
The consensus EPS estimate for MoonLake Immunotherapeutics for the quarter ending Dec 31, 2026 is -$0.84 from 15 analysts, with estimates from -$0.99 to -$0.69.
How often does MLTX beat earnings estimates?
MoonLake Immunotherapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -7.54%.
MLTX pages: Overview, Earnings, Forecast, Financials, Competitors